(Reuters) - The medicine has already been advanced into late stage
testing for acute treatment of migraine in adults. If it is
eventually approved, it could become the first new class of
migraine treatments on the market since 1991, Merck said.
The company said it remains on track to apply for U.S.
approval of MK-0974 in 2009.
Read more at Reuters.com Government Filings News
testing for acute treatment of migraine in adults. If it is
eventually approved, it could become the first new class of
migraine treatments on the market since 1991, Merck said.
The company said it remains on track to apply for U.S.
approval of MK-0974 in 2009.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment